Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 9:17:101636.
doi: 10.1016/j.bonr.2022.101636. eCollection 2022 Dec.

MSC-EV therapy for bone/cartilage diseases

Joe Kodama  1 , Kevin J Wilkinson  1 , Satoru Otsuru  1
Affiliations

MSC-EV therapy for bone/cartilage diseases

Joe Kodama et al. Bone Rep. .

Abstract

Mesenchymal stromal cells (MSCs) have been utilized in cell therapy for various diseases. Recent studies have demonstrated that extracellular vesicles (EVs) released by MSCs play an important role in their therapeutic activities. EVs contain a variety of bioactive molecules such as proteins, messenger RNAs (mRNAs), and micro RNAs (miRNAs) and modify the function of the recipient cells by transferring these molecules. Despite the promising potential of EV therapy as a substitute for MSC therapy, there are challenges that need to be addressed for the clinical success of EV therapy. EV quality has been shown to vary from batch to batch and preparation to preparation. As the consistency and reproducibility of therapeutic effects rely on the quality of EVs, it is necessary to establish techniques to manufacture scalable amounts of EVs with the same quality. In this manuscript, we discuss the potential factors that affect EV quality. We then introduce pre-clinical studies of EV therapy for bone/cartilage diseases such as osteoarthritis, rheumatoid arthritis, and osteoporosis.

Keywords: Extracellular vesicles (EVs); MSC-EV therapy; Mesenchymal stromal cells (MSCs); Osteoarthritis; Osteoporosis; Rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH, R21AR077654).

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adlerz K. Strategies for scalable manufacturing and translation of MSC-derived extracellular vesicles. Stem Cell Res. 2020;9 - PubMed
    1. Akpancar S., Tatar O., Turgut H., Akyildiz F., Ekinci S. The current perspectives of stem cell therapy in orthopedic surgery. Arch. Trauma Res. 2016;5 doi: 10.5812/atr.37976. - DOI - PMC - PubMed
    1. Albanese M., Chen Y.-F.A., Hüls C., Gärtner K., Tagawa T., Mejias-Perez E., Keppler O.T., Göbel C., Zeidler R., Shein M., Schütz A.K., Hammerschmidt W. MicroRNAs are minor constituents of extracellular vesicles that are rarely delivered to target cells. PLoS Genet. 2021;17 doi: 10.1371/journal.pgen.1009951. - DOI - PMC - PubMed
    1. Alexander D.D., Mink P.J., Adami H.-O., Cole P., Mandel J.S., Oken M.M., Trichopoulos D. Multiple myeloma: a review of the epidemiologic literature. Int. J. Cancer. 2007;120:40–61. doi: 10.1002/ijc.22718. - DOI - PubMed
    1. de Almeida Fuzeta M., Bernardes N., Oliveira F.D., Costa A.C., Fernandes-Platzgummer A., Farinha J.P., Rodrigues C.A.V., Jung S., Tseng R.-J., Milligan W., Lee B., Castanho M.A.R.B., Gaspar D., Cabral J.M.S., da Silva C.L. Scalable production of human mesenchymal stromal cell-derived extracellular vesicles under serum-/Xeno-free conditions in a microcarrier-based bioreactor culture system. Front. Cell Dev. Biol. 2020;8 doi: 10.3389/fcell.2020.553444. - DOI - PMC - PubMed